Sign In
Buy CRSP
$48.15
+1.16 (+2.47%)
At Close: Jul 21, 2026
CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments
08:00am, Thursday, 23'rd May 2024
-Naimish Patel, M.D., appointed to Chief Medical Officer- -Julianne Bruno, M.B.A.
7 Must-Buy Stocks if You Only Have $1,000 to Spend: May Edition
09:22am, Wednesday, 22'nd May 2024
If you have a budget of around $1,000 and you'd like to buy some solid stocks to beat the market, I've got you covered! The stocks in this article total around ~$383 as of writing if you bought one of
Is CRISPR Therapeutics a Millionaire Maker?
09:10am, Wednesday, 22'nd May 2024
CRISPR Therapeutics is finally at the cusp of profitability. Its pipeline has quite a few promising opportunities beyond the approved therapies.
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
06:40am, Wednesday, 22'nd May 2024
Indexes are extending bull market gains, reaching new records. It's not too late to get in on the action -- history suggests this bull market could have much farther to go.
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by National Bank of Canada FI
05:06am, Monday, 20'th May 2024
National Bank of Canada FI lessened its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 63.7% during the fourth quarter, according to the company in its most recent 13F filing wit
Is CRISPR Therapeutics Stock a Buy?
09:30am, Friday, 17'th May 2024
CRISPR develops cutting-edge therapies that could be transformative. The gene-editing specialist has launched its first approved treatment.
7 No-Brainer Stocks to Buy and Hold for the Next 20 Years: May 2024
06:40am, Thursday, 16'th May 2024
They say the best time to invest was 20 years ago. And indeed, that's not too long after the early 2000s recession bottomed out.
Is CRISPR Stock Going to $95? 1 Wall Street Analyst Thinks So.
11:11am, Wednesday, 15'th May 2024
CRISPR reported rising losses on deeply lower revenue last week. The gene-editing biotech is, however, making progress on several therapies, and ready to bring its first treatment to market.
2 Healthcare Stocks to Buy and Hold for Great Long-Term Potential
10:07am, Tuesday, 14'th May 2024
The healthcare sector has attractive stocks for any investment strategy. Pfizer has an impressive product pipeline and an attractive valuation as well.
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
10:02am, Monday, 13'th May 2024
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
The 3 Best Cathie Wood Stocks to Buy in May 2024
06:04am, Monday, 13'th May 2024
As investors, we are always aiming to reevaluate our portfolios and make additions. However, we can often get lost in the vastness of the markets when deciding on just a handful of companies.
The 3 Most Undervalued Biotech Stocks to Buy in May 2024
10:00am, Saturday, 11'th May 2024
The biotech sector holds some of the most promising and popular stocks on the market. With the promise of breakthrough treatments that generate billions of dollars annually, investors always look for
CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss
12:01pm, Thursday, 09'th May 2024
CRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims that the commercial launch for the first ever CRISPR-based gene therapy is progressing well.
CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference
08:30am, Thursday, 09'th May 2024
ZUG, Switzerland and BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseas
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates
06:11pm, Wednesday, 08'th May 2024
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.43 per share versus the Zacks Consensus Estimate of a loss of $1.63. This compares to loss of $0.67 per share a year ago.
